Linked Life Data

9252714

Source:http://linkedlifedata.com/resource/pubmed/id/9252714

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4A
pubmed:dateCreated
1997-9-3
pubmed:abstractText
Vinorelbine is active in a variety of malignancies. The most common side effects are leukopenia and granulocytopenia, moreover Vinorelbine is a vescicant and venous irritant, the incidence of the latter being 10-26% in patients who received VNB as a 20-30 minute peripheral infusion. To prevent venous toxicity we have carried out a study in order to evaluate the efficacy of Defibrotide in this issue.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0250-7005
pubmed:author
pubmed:issnType
Print
pubmed:volume
17
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2775-7
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed:articleTitle
Defibrotide in the prevention of venous irritation by vinorelbine administration.
pubmed:affiliation
Instituto Nazionale per la Ricerca sul Cancro, Sezione di Messina, Italy.
pubmed:publicationType
Journal Article, Clinical Trial, Clinical Trial, Phase II